Le Lézard
Classified in: Health
Subject: ACC

Vitrolife Group to host Capital Markets Day on 12 December 2023


GOTHENBURG, Sweden, Nov. 30, 2023 /PRNewswire/ -- Vitrolife AB (publ) today announced that it will host a Capital Markets Day presentation for the investment community on 12 December 2023, 10:00-15:30 CET in Stockholm. 

Bronwyn Brophy, Chief Executive Officer, and Patrik Tolf, Chief Financial Officer, will be joined by leading experts and practitioners in the reproductive health industry to share their thoughts on the future of infertility care around the world. The Executive Management team will set out the new corporate strategy to drive sustainable, profitable growth capitalising on the mega market trends and leveraging the Vitrolife Group core strengths and capabilities. They will also discuss their plans to bring more much needed innovation to the reproductive health market.

For further detail on the Capital Markets Day, including the agenda and speakers, please visit https://www.vitrolifegroup.com/en/investor-relations/presentations/capital-markets-update-2023. We welcome in-person attendance, where you can also explore the Vitrolife Group marketplace, at Hotel At Six, Brunkebergstorg 6, Stockholm, Sweden. Please RSVP by contacting [email protected] no later than 7 December 2023. Access to a live webcast will be available on our website, beginning 15 minutes prior to the start time of the presentation, and a replay will be available following the event.

Gothenburg, 30 November 2023
VITROLIFE AB (publ)

Contact: 

Patrik Tolf, CFO, phone +46 (0) 31 766 90 21

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

The following files are available for download:

https://mb.cision.com/Main/1031/3885960/2466467.pdf

Vitrolife Group to host Capital Markets Day on 12 December 2023

 

SOURCE Vitrolife AB (publ)


These press releases may also interest you

at 04:05
PhoreMost Introduces GlueSEEKER Platform for Discovery of Molecular Glue Degraders
PhoreMost Ltd., a leading UK biopharmaceutical company unlocking the next generation of drug targets, today announced the introduction of GlueSEEKERtm. The new phenotypic screening platform expands the Company's capabilities in this emerging...

at 04:03
Oncology Events in Poland Solidify Collaboration with NCCN
The National Comprehensive Cancer Network® (NCCN®)?a global nonprofit responsible for leading cancer treatment guidelines?is taking part in two events in Warsaw focused on advancing...

at 03:52
Simcere Phar-maceuticals Presented Six Studies on Sanbexin® at ESOC 2024
The 10th European Stroke Organization Congress (ESOC), held in Basel, Switzerland from May 15 to 17, 2024, showcased six studies on Sanbexin® (Edaravone and Dexborneol Concentrated Solution for Injection) and a new dosage form of sublingual tablets...

at 03:12
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Clearance
GC Biopharma (006280. KS) and Novel Pharma have announced that the U.S. FDA has cleared the investigational new drug (IND) application for their jointly developed MPSIIIA (Sanfilippo Syndrome Type A) treatment, GC1130A....

at 03:05
PathAI Announces Early Access Program to Drive Adoption of AISight Image Management System in Anatomic Pathology Laboratories Across Mainland Europe
PathAI, a global leader in AI-powered pathology, today announced a new Early Access Program (EAP) to drive adoption of its AISightTM Image Management System (IMS) in Mainland Europe.1 Earlier in 2023, PathAI announced a similar program for...

at 03:00
Pheon Therapeutics announces $120m Series B financing to fund development of its differentiated ADC pipeline
Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, today announces the completion of a $120m Series B financing to fund the development of its...

More news about Health...


News published on and distributed by: